Clinical Trial Search Results
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery after Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection.
This study is currently enrolling.
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of POI in subjects undergoing open or laparoscopic BR. Straight, hand-assisted, and robotically-assisted la ...
REIMAGINE 4 - Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or withouT an SGLT2 inhibitor
This study is currently enrolling.
Study Purpose: The purpose of this study is to look at how much a new investigational medicine called CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to another type 2 diabetes medicine call ...
Renal Tumors Classification, Biology, and Banking Study
This study is currently enrolling.
Over the past years, many studies have been done for children with kidney tumors. Each study done has increased what we know about these tumors and has helped doctors plan treatment for subjects with these tumors. Researchers n ...
REST: The role of type 2 diabetes on skeletal muscle atrophy and recovery following bed rest in older adults
This study is currently enrolling.
Study Purpose: To better understand the role of Type 2 Diabetes on skeletal muscle atrophy and recovery following bed rest. Study Duration: 14 weeks Study Commitment: 2 Screening Visits 5 Pre-Bedrest Visits 10 Consecutiv ...
REVITALIZE-1: A Prospective randomized, double-blind, sham-controlled, multi-center pivotal study to evaluate the efficacy and safety of Duodenal Mucosal Resurfacing (DMR) using the Revita system in subjects with type 2 diabetes on insulin therapy.
This study is currently enrolling.
Study Purpose: The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita System compared to a sham. To be enrolled in this study, you must meet certain requirements. You m ...
S1703, Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
This study is currently enrolling.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. ...
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
This study is currently enrolling.
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are rando ...
S1937, A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
This study is currently enrolling.
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribu ...
S2012, Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
This study is currently enrolling.
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatm ...